FCAA does the following:
- Leave the payment data period for the next three-year PAMA cycle the same, 1H2019.
- Claims paid during 1H2019 for active codes in 1H2019 will be part of the next PAMA data collection.
- Delay the data collection from 1Q2020 to 1Q2021.
- Delay the implementation of new prices to January 2022.
CMS notes that another time cycle is not changed, in its view. This time cycle provided 10% pay cuts (at the max) in Year 1,2,3 under PAMA, and 15% pay cuts (at the max) in Year 4,5,6. Since 2020 is Year 3, pay cuts are limited to 10%, but since 2021 is still year 4, pay cuts will be 15%.
Whether lab tests get a 15% cut in CY2021 depends on whether the 2020 price is still 15% higher than the price median found based on 2017 data.
CMS updated the top part of its PAMA page, here. See table (click to enlarge) clipped below.
click to enlarge |
By my informal tally, comparing 2020 current prices to the median of 2017 reported private payer prices, about 206 CLFS CPT codes will have a 15% cut in CY2021 if CMS's update is correct. Another group of about 390 will have a 10-15% cut and finally about 130 will have a 0-9% cut.
I've put my personal best-effort spreadsheet in the cloud here. This Excel has two tabs; one sorted by percent cut 2021 (my prediction), and one sorted by CPT.
Recall there were some huge anomalies in PAMA reporting pricing; for example, 81341 TRB gene rearrangement had a CPT price of $68 in 2017 but a PAMA median price target of one penny. 81435 Lynch Panel had a CMS 2017 price of $802, but a PAMA median price target of $37.99.
I've put my personal best-effort spreadsheet in the cloud here. This Excel has two tabs; one sorted by percent cut 2021 (my prediction), and one sorted by CPT.
Recall there were some huge anomalies in PAMA reporting pricing; for example, 81341 TRB gene rearrangement had a CPT price of $68 in 2017 but a PAMA median price target of one penny. 81435 Lynch Panel had a CMS 2017 price of $802, but a PAMA median price target of $37.99.